Exercise, hormone therapy, and lipoproteins in women

Journal of the American Geriatrics Society

Volumn 44, Issue 3, 1996, Pages 331-332

  Grady, Deborah ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; BLOOD; ESTROGEN THERAPY; EXERCISE; FEMALE; HUMAN; MIDDLE AGED; NOTE; POSTMENOPAUSE;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ESTROGEN REPLACEMENT THERAPY; EXERCISE; FEMALE; HUMANS; LIPOPROTEINS; MIDDLE AGED; POSTMENOPAUSE;

EID: 0030094481     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1996.tb00926.x     Document Type: Editorial

References (30)

1. Manolio T, Pearson T, Wenger N, et al., Cholesterol and heart disease in older persons and women: Review of an NHLBI workshop. Ann Epidemiol 1992; 2: 161-176.
2. Corti M-C, Guralnik J, Salive M, et al., HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995; 274: 539-544.
3. Bass K, Newschaffer C, Klag M, Bush T,. Plasma liproprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153: 2209-2216.
4. Hulley S, Avins A,. Asymptomatic hypertriglceridaemia. Insufficient evidence to treat. Br Med J 1992; 304: 394-396.
5. NIH Consensus Development Panel On Triglyceride, High-Density Lipoprotein and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993; 269: 505-510.
6. Garber A, Avins A,. Triglyceride concentration and coronary heart disease. Not yet proved of value as a screening test. Br Med J 1994; 309: 2-3.
7. Hulley S, Rosenman R, Bawol R, Brand R,. Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease. N Engl J Med 1980; 302: 1383-1389.
8. Avins A, Haber R, Hulley S,. The status of hypertriglyceridemia as a risk factor for coronary heart disease. Clin Lab Med 1989; 9: 153-168.
9. Muldoon M, Manuck S, Matthews K,. Lowering cholesterol concentrations and mortality: A review of primary prevention trials. Br Med J 1990; 301: 309-314.
10. Roussouw J, Lewis B, Rifkind B,. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323: 1112-1119.
11. Hulley S, Newman T, Grady D, et al., Should we be measuring blood cholesterol levels in young adults. JAMA 1993; 269: 1416-1419.
12. Walsh J, Grady D,. Treatment of hyperlipidemia in women. JAMA 1995; 274: 1152-1158.
13. Binder E, Birge S, Kohrt W,. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women. J Am Geriatr Soc 1995; 44: xxx-xxx.
14. Rich-Edwards J, Manson J, Hennekens C, Buring J,. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332: 1758-1766.
15. Hammar M, Brynhildsen J, Wyon Y, et al., The effects of physical activity on menopausal symptoms and metabolic changes around menopause. Menopause 1995; 2: 201-209.
16. Blair S, Kohn HI, Paffenbarger RJ, et al., Physical fitness and all-cause mortality: A prospective study of healthy men and women. JAMA 1989; 262: 2395-2401.
17. LaRosa J,. Effect of estrogen replacement therapy on lipids: Implications for cardiovascular risk. J Reprod Med 1985; 30 (suppl 10): 811-813.
18. Knopp R,. Cardiovascular effects of endogenous and exogenous sex hormones over a woman's lifetime. Am J Obstet Gynecol 1988; 158: 1630-1643.
19. Krauss RM, Perlman JA, Ray R, Petitti D,. Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women. Am J Obstet Gynecol 1988; 158: 1606-1611.
20. Miller V, Muesing R, LaRosa J, et al., Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol 1991; 77: 235-240.
21. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
22. Ettinger B, Selby J, Citron J, et al., Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83: 693-700.
23. Williams D, Voigt B, Fu Y, et al., Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol 1994; 84: 787-793.
24. Bush TL,. Noncontraceptive estrogen use and risk of cardiovascular disease: An overview and critique of the literature. In:, Korenman SG, ed. The Menopause. Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Sereno Symposia, 1990, pp 211-223.
25. Stampfer MJ, Colditz GA,. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
26. Grady D, Gebretsadik T, Kerlikowske K, et al., Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995; 85: 304-313.
27. Grady D, Rubin S, Petitti D, et al., Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
28. Colditz G, Hankinson S, Hunter D, et al., The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-1593.
29. Cauley J, Cummings SR, Black DM, et al., Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990; 163: 1438-1444.
30. Barrett-Connor E, Bush T,. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-1867.